RapidClaims, an Indian startup specializing in AI-driven revenue cycle management for US healthcare providers, has refuted reports about an ongoing $30 million Series B fundraising round led by WestBridge Capital at a valuation of $200 million.
- RapidClaims denies current fundraising talks with WestBridge Capital.
- Startup offers AI software automating medical coding and claims processing.
- Series A in 2025 raised $8M led by Accel, aimed at expanding US market reach.
What happened
Initial reports emerged indicating that RapidClaims was negotiating a $30 million Series B investment led by WestBridge Capital, valuing the startup around $200 million. This funding round was said to include participation from previous investors Accel and Together Fund. RapidClaims is known for its AI-driven SaaS products that assist healthcare providers in automating revenue cycle management tasks.
Following these reports, RapidClaims' founder and CEO Dushyant Mishra publicly denied the fundraising discussions and the valuation figures. Neither WestBridge Capital nor RapidClaims provided comments at the time of the initial publication.
Why it matters
Healthcare revenue cycle management faces significant challenges with billing errors, denied claims, and delayed reimbursements, especially in the US market. RapidClaims uses artificial intelligence to streamline processes such as medical coding, clinical documentation, and claims recovery, aiming to reduce manual errors and accelerate payments.
The startup’s ability to secure substantial funding would signal growing investor confidence in AI's role in automating healthcare administration. RapidClaims’ prior Series A round in April 2025 raised $8 million to scale product capabilities and market presence, underscoring strong momentum in this space among FQHCs, physician groups, and ambulatory centers.
What to watch next
Industry observers will be interested in RapidClaims’ next financing moves and product development, especially its expansion into inpatient coding for hospital admissions, which could broaden its addressable market. Continued innovation in AI automation solutions remains critical as US healthcare providers seek efficiencies amid rising administrative burdens.
Further signals about investor appetite for healthcare automation startups will emerge from other recent fundraises, such as Confido Health’s $12.5 million Series A extension and Consint.AI’s funding to enhance AI fraud detection and claims processing. RapidClaims’ progress could influence funding trends in India's healthtech ecosystem targeting international markets.